Posted by Michael Wonder on 17 Jan 2025
Rybrevant plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR mutated advanced lung cancer
16 January 2025 - Phase 3 MARIPOSA-2 study showed Rybrevant in combination with carboplatin and pemetrexed significantly improved progression-free survival compared to carboplatin and pemetrexed alone.
Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance for Rybrevant (amivantamab for injection) in combination with carboplatin and pemetrexed (platinum-based chemotherapy) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.
